Halifax, Nova Scotia, Canada Canadian Medical Discoveries Fund is the famous VC, which was founded in 1994. The main department of described VC is located in the Halifax. The company was established in North America in Canada.
Comparing to the other companies, this Canadian Medical Discoveries Fund performs on 2 percentage points more the average number of lead investments. The top activity for fund was in 2008. The fund is constantly included in less than 2 investment rounds annually. The common things for fund are deals in the range of 10 - 50 millions dollars. The real fund results show that this VC is 14 percentage points less often commits exit comparing to other companies. The top amount of exits for fund were in 2013.
The standard case for the fund is to invest in rounds with 5 partakers. Despite the Canadian Medical Discoveries Fund, startups are often financed by GeneChem, BDC Venture Capital, Novo Holdings. The meaningful sponsors for the fund in investment in the same round are GrowthWorks Capital, BDC Venture Capital, GeneChem. In the next rounds fund is usually obtained by BDC Venture Capital, GrowthWorks Capital, VenGrowth Asset Management.
The fund has exact preference in a number of founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight Cytochroma, Viron Therapeutics, Agrisoma Biosciences. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Canada. Among the most popular fund investment industries, there are Health Care, Pharmaceutical.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Ag Startup Engine | Ames, Iowa, United States |
| Appaloosa Management | Florida, Miami Beach, United States |
| Baker Capital Corporation | Edmond, Oklahoma, United States |
| De Zhong Hui Keji Kaifa Zhongxin | China, Chongqing, Chongqing Shi |
| Deutsche Bank Alex. Brown | Baltimore, Maryland, United States |
| ES & Partner ventures | Connecticut, Stamford, United States |
| European Space Agency Business Incubation Centre, Noordwijk | France, Ile-de-France, Paris |
| Excalibur Technologies | - |
| GE Capital Life Science and Technology Finance | California, Los Altos, United States |
| Huafengda Youxian Wangluo | Beijing, China, Shunyi |
| India Educational Investment Fund | - |
| Kushiro Manufacturing | Hokkaido Prefecture, Japan, Kushiro |
| Leadpath Nigeria | Lagos, Lagos, Nigeria |
| Maotai Jianxin (Guizhou) Investment Fund | China, Guiyang, Guizhou |
| Southern Progress Corporation | - |
| Spring Lake Equity Partners | Boston, Massachusetts, United States |
| UT Research Institute | Chiyoda, Japan |
| Viventures Partners SA | France, Ile-de-France, Paris |
| YONDEN | Japan, Kagawa Prefecture, Takamatsu |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Natrix Separations | $19M | 03 Sep 2008 | Old Toronto, Ontario, Canada | ||
| $35M | 30 Jul 2008 | Kingston, Ontario | |||
Gemin X Pharmaceuticals | $38M | 03 Jul 2008 | Montreal, Quebec, Canada | ||
Inimex Pharmaceuticals | $22M | 02 Jun 2008 | Burnaby, British Columbia, Canada | ||
| $70M | 08 Feb 2007 | Cambridge, Massachusetts, United States | |||
Protiva Biotherapeutics | $5M | 13 Jul 2006 | Seattle, Washington, United States | ||
Viron Therapeutics | $20M | 16 May 2006 | London, England, United Kingdom | ||
Ambit Biosciences | $31M | 12 May 2005 | San Diego, California, United States | ||
Inimex Pharmaceuticals | $1M | 08 Dec 2004 | Burnaby, British Columbia, Canada |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Natrix Separations | $19M | 03 Sep 2008 | Old Toronto, Ontario, Canada | ||
| $35M | 30 Jul 2008 | Kingston, Ontario | |||
Gemin X Pharmaceuticals | $38M | 03 Jul 2008 | Montreal, Quebec, Canada | ||
Inimex Pharmaceuticals | $22M | 02 Jun 2008 | Burnaby, British Columbia, Canada | ||
| $70M | 08 Feb 2007 | Cambridge, Massachusetts, United States | |||
Protiva Biotherapeutics | $5M | 13 Jul 2006 | Seattle, Washington, United States | ||
Viron Therapeutics | $20M | 16 May 2006 | London, England, United Kingdom | ||
Ambit Biosciences | $31M | 12 May 2005 | San Diego, California, United States | ||
Inimex Pharmaceuticals | $1M | 08 Dec 2004 | Burnaby, British Columbia, Canada |
